Mechanisms of tumour metastasis

European Journal of Cancer

Volumn 34, Issue 2, 1998, Pages 214-221

  Meyer, T ^a   Hart, I R ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CADHERIN; CELL ADHESION MOLECULE; INTEGRIN; MATRIX METALLOPROTEINASE; SELECTIN; UROKINASE RECEPTOR;

ANGIOGENESIS; ARTICLE; CLINICAL PATHWAY; ENZYME BINDING; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS POTENTIAL; PATHOPHYSIOLOGY; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0032512914     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)10129-0     Document Type: Article

References (113)

1. 1. Behrens J, Mareel M, Van Roy FM, Birchmeier W. Dissecting tumor cell invasion: epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell-cell adhesion. J Cell Biol 1989, 108, 2435-2447.
2. 2. Behrens J. The role of cell adhesion molecules in cancer invasion and metastasis. Breast Cancer Res Treat 1993, 24, 175-184.
3. 3. Sommers CL, Thompson EW, Torri JA, Kemler R, Gelmann EP, Byers SW. Cell adhesion molecule uvomorulin expression in human breast cancer cell lines: relationship to morphology and invasive capacities. Cell Growth and Differ 1991, 2, 365-372.
4. 4. Doki Y, Shiozaki H, Tahara H, et al. Correlation between E-cadherin expression and invasiveness in vitro in a human esophageal cancer cell line. Cancer Res 1993, 53, 3421-3426.
5. 5. Mbalaviele G, Dunstan CR, Sasaki A, Williams PJ, Mundy GR, Yoneda T. E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model. Cancer Res 1996, 56, 4063-4070.
6. 6. Bracke ME, Charlier C, Bruyneel EA, Labit C, Mareel MM, Castronovo V. Tamoxifen restores the E-cadherin function in human breast cancer MCF-7/6 cells and suppresses their invasive phenotype. Cancer Res 1994, 54, 4607-4609.
7. 7. Charlier C, Bruyneel E, Lechanteur C, Bracke M, Mareel M, Castronovo V. Enhancement of tamoxifen-induced E-cadherin function by Ca2+ channel antagonists in human breast cancer MCF7/6 cells. Eur J Pharmacol 1996, 317, 413-416.
8. 8. Gamallo C, Palacios J, Suarez A, et al. Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma. Am J Pathol 1993, 142, 987-993.
9. 9. Palacios J, Benito N, Pizarro A, et al. Anomalous expression of P-cadherin in breast carcinoma. Correlation with E-cadherin expression and pathological features. Am J Pathol 1995, 146, 605-612.
10. 10. Siitonen SM, Kononen JT, Helin HJ, Rantala IS, Holli KA, Isola JJ. Reduced E-cadherin expression is associated with invasiveness and unfavorable prognosis in breast cancer. Am J Clin Pathol 1996, 105, 394-402.
11. 11. Gupta SK, Douglas Jones AG, Jasani B, Morgan JM, Pignatelli M, Mansel RE. E-cadherin (E-cad) expression in ductal carcinoma in situ (DCIS) of the breast. Virchows Arch 1997, 430, 23-28.
12. 12. Umbas R, Schalken JA, Aalders TW, et al. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res 1992, 52, 5104-5109.
13. 13. Umbas R, Isaacs WB, Bringuier PP, et al. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 1994, 54, 3929-3933.
14. 14. Cheng L, Nagabhushan M, Pretlow TP, Amini SB, Pretlow TG. Expression of E-cadherin in primary and metastatic prostate cancer. Am J Pathol 1996, 148, 1375-1380.
15. 15. Matsui S, Shiozaki H, Inoue M, et al. Immunohistochemical evaluation of alpha-catenin expression in human gastric cancer. Virchows Arch 1994, 424, 375-381.
16. 16. Bringuier PP, Umbas R, Schaafsma HE, Karthaus HF, Debruyne FM, Schalken JA. Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumours. Cancer Res 1993, 53, 3241-3245.
17. 17. Shimazui T, Schalken JA, Giroldi LA, et al. Prognostic value of cadherin-associated molecules (alpha-, beta-, and gamma-catenins and p120cas) in bladder tumors. Cancer Res 1996, 56, 4154-4158.
18. 18. Syrigos KN, Krausz T, Waxman J, et al. E-cadherin expression in bladder cancer using formalin-fixed, paraffin-embedded tissue: correlation with histopathological grade, tumour stage and survival. Int J Cancer 1995, 64, 367-370.
19. 19. Dorudi S, Sheffield JP, Poulsom R, Northover JM, Hart IR. E-cadherin expresion in colorectal cancer. An immunocytochemical and in situ hybridization study. Am J Pathol 1993, 142, 981-986.
20. 20. Dorudi S, Hanby AM, Poulsom R, Northover J, Hart IR. Level of expression of E-cadherin mRNA in colorectal cancer correlates with clinical outcome. Br J Cancer 1995, 71, 614-616.
21. 21. Pignatelli M, Ansari TW, Gunter P, et al. Loss of membranous E-cadherin expression in pancreatic cancer: correlation with lymph node metastasis, high grade, and advanced stage. J Pathol 1994, 174, 243-248.
22. 22. Nakanishi Y, Ochiai A, Akimoto S, et al. Expression of E-cadherin, alpha-catenin, beta-catenin and plakoglobin in esophageal carcinomas and its prognostic significance: immunohistochemical analysis of 96 lesions. Oncology 1997, 54, 158-165.
23. 23. Rimm DL, Sinard JH, Morrow JS. Reduced alpha-catenin and E-cadherin expression in breast cancer [see comments]. Lab Invest 1995, 72, 506-512.
24. 24. Su LK, Vogelstein B, Kinzler KW. Association of the APC tumor suppressor protein with catenins. Science 1993, 262, 1734-1737.
25. 25. Behrens J, von Kries JP, Kuhl M, et al. Function interaction of β-caterin with the transcription factor LEF-1. Nature 1996, 382, 638-642.
26. -/- colon carcinoma. Science 1997, 275, 1784-1787.
27. 27. Morin PJ, Sparks AB, Korinek V, et al. Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science 1997, 275, 1787-1790.
28. 28. Rubinfeld R, Robbins P, El-Gamil M, Albert I, Porfiri E, Polakis P. Stabilization of β-catenin by genetic defects in melanoma cell lines. Science 1997, 275, 1790-1792.
29. 29. Chen H, Paradies NE, Fedor-Chaiken M, Brackenbury R. E-cadherin mediates adhesion and suppresses cell motility via distinct mechanisms. J Cell Sci 1997, 110, 345-356.
30. 30. Hynes RO. Integrins: versatility, modulation, and cell adhesion. Cell 1992, 69, 11-25.
31. 31. Brooks PC, Montgomery AM, Rosenfeld M, et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994, 79, 1157-1164.
32. 32. Montgomery AM, Reisfeld RA, Cheresh DA. Integrin alpha v beta 3 rescues melanoma cells from apoptosis in three-dimensional dermal collagen. Proc Natl Acad Sci USA 1994, 91, 8856-8860.
33. 33. Cheresh DA, Mecham RP. Integrins: Molecular and Biological Responses to the Extracellular Matrix (Monograph). London Academic Press Inc., 1994.
34. 34. Gui GPH, Wells CA, Yeomans P, Jordan SE, Vinson GP, Carpenter R. Integrin expression in breast cancer cytology - a novel predictor of axillary metastasis. Eur J Surg Oncol 1996, 22, 254-258.
35. 35. Koukoulis GK, Virtanen I, Korhonen M, Laitinen L, Quaranta V, Gould VE. Immunohistochemical localization of integrins in the normal, hyperplastic, and neoplastic breast. Correlations with their functions as receptors and cell adhesion molecules. Am J Pathol 1991, 139, 787-799.
36. 36. Weinel RJ, Rosendahl A, Pinschmidt E, Kisker O, Simon B, Santoso S. The alpha 6-integrin receptor in pancreatic carcinoma. Gastroenterology 1995, 108, 523-532.
37. 37. Hall PA, Coates P, Lemoine NR, Horton MA. Characterization of integrin chains in normal and neoplastic human pancreas. J Pathol 1991, 165, 33-41.
38. 38. Pignatelli M, Smith ME, Bodmer WF. Low expression of collagen receptors in moderate and poorly differentiated colorectal adenocarcinomas. Br J Cancer 1990, 61, 636-638.
39. 39. Stallmach A, von Lampe B, Matthes H, Bornhoft G, Riecken EO. Diminished expression of integrin adhesion molecules on human colonic epithelial cells during the benign to malignant tumour transformation. Gut 1992, 33, 342-346.
40. 40. Koretz K, Schlag P, Boumsell L, Moller P. Expression of VLA-alpha 2, VLA-alpha 6 and VLA-beta 1 chains in normal mucosa and adenomas of the colon, and in colon carcinomas and their liver metastases. Am J Pathol 1991, 138, 741-750.
41. 41. Lindmark G, Gerdin B, Pahlman L, Glimelius B, Gehlsen K, Rubin K. Interconnection of integrins alpha 2 and alpha 3 and structure of the basal membrane in colorectal cancer: relation to survival. Eur J Surg Oncol 1993, 19, 50-60.
42. 42. Suzuki S, Takahashi T, Nakamura S, et al. Alterations of integrin expression in human lung cancer. Japanese J Cancer Res 1993, 84, 16-74.
43. 43. Roussel E, Gingras MC, Ro JY, Branch C, Roth JA. Loss of alpha 1 beta 1 and reduced expression of other beta 1 integrins and CAM in lung adenocarcinoma compared with pneumocytes. J Surg Oncol 1994, 56, 198-208.
44. 44. Natali PG, Nicotra MR, Botti C, Mottolese M, Bigotti A, Segatto O. Changes in expression of alpha 6 beta 4 integrin heterodimer in primary and metastatic breast cancer. Br J Cancer 1992, 66, 318-322.
45. 45. Albelda SM, Mette SA, Elder DE, et al. Integrin distribution in malignant melanoma: association of the β3 subunit with tumour progression. Cancer Res 1990, 50, 6757-6764.
46. 46. Giancotti FG, Ruoslahti E. Elevated levels of the alpha 5 beta 1 fibronectin receptor suppress the transformed phenotype of Chinese hamster ovary cells. Cell 1990, 60, 849-859.
47. 47. Zutter MM, Santoro SA, Staatz WD, Tsung YL. Re-expression of the alpha 2 beta 1 integrin abrogates the malignant phenotype of breast carcinoma cells. Proc Natl Acad Sci USA 1995, 92, 7411-7415.
48. 48. Humphries MJ, Olden K, Yamada KM. A synthetic peptide from fibronectin inhibits experimental metastasis of murine melanoma cells. Science 1986, 233, 467-470.
49. 49. Mitjans F, Sander D, Adan J, et al. An anti-alpha v integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice. J Cell Sci 1995, 108, 2825-2838.
50. 50. Newton SA, Reeves EJ, Gralnick H, et al. Inhibition of experimental metastasis of human breast carcinoma in athymic nude mice by anti-α5β1 fibronectin receptor integrin antibodies. Int J Oncology 1995, 6, 1063-1070.
51. 51. Pasqualini R, Bourdoulous S, Koivunen E, Woods V, Rouslahti E. A polymeric form of fibronectin has antimetastatic effects against multiple tumour types. Nature Medicine 1996, 2, 1197-1203.
52. 52. Palecek SP, Loftus JC, Ginsberg MH, Lauffenburger DA, Horwitz AF. Integrin-ligand binding properties govern cell migration speed through cell-substratum adhesiveness. Nature 1997, 385, 537-540.
53. 53. Herzberg F, Schoning M, Schirner M, Topp M, Thiel E, Kreuser ED. IL-4 and TNF-alpha induce changes in integrin expresion and adhesive properties and decrease the lung-colonizing potential of HT-29 colon-carcinoma cells. Clin Exp Metastasis 1996, 14, 165-175.
54. 54. Kim LT, Yamada KM. The regulation of expression of integrin receptors. Proc Soc Exp Biol Med 1997, 214, 123-131.
55. 55. Meyer T, Marshall JF, Hart IR. Expression of alpha v integrins and vitronectin receptor identity in breast cancer cell lines. Br J Cancer 1997, in press.
56. 56. Maemura M, Akiyama SK, Woods VLJr, Dickson RB. Expression and ligand binding of alpha 2 beta 1 integrin on breast carcinoma cells. Clin Exp Metastasis 1995, 13, 223-235.
57. 57. Springer TA. Adhesion receptors of the immune system. Nature 1990, 346, 425-434.
58. 58. Natali P, Nicotra MR, Cavaliere R, et al. Differential expression of intercellular adhesion molecule 1 in primary and metastatic melanoma lesions. Cancer Res 1990, 50, 1271-1278.
59. 59. Elices MJ, Osborn L, Takada Y, et al. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell 1990, 60, 577-584.
60. 60. Tomita Y, Saito T, Saito K, Oite T, Shimizu F, Sato S. Possible significance of VLA-4 (alpha 4 beta 1) for hematogenous metastasis of renal-cell cancer. Int J Cancer 1995, 60, 753-758.
61. 61. Hart IR, Birch M, Marshall JF. Cell adhesion receptor expression during melanoma progression and metastasis. Cancer Metastasis Rev 1991, 10, 115-128.
62. 62. Paavonen T, Tiisala S, Majuri ML, Bohling T, Renkonen R. In vivo evidence of the role of alpha 4 beta 1-VCAM-I interaction in sarcoma but not in carcinoma extravasation. Int J Cancer 1994, 58, 298-302.
63. 63. Buckley CD, Doyonnas R, Newton JP, et al. Identification of alpha v beta 3 as a heterotypic ligand for CD31/PECAM-1. J Cell Sci 1996, 109, 437-445.
64. 64. Dejana E, Martin Padura I, Lauri D, et al. Endothelial leukocyte adhesion molecule-1-dependent adhesion of colon carcinoma cells to vascular endothelium is inhibited by an antibody to Lewis fucosylated type I carbohydrate chain. Lab Invest 1992, 66, 324-330.
65. x blood group antigens in human gastric carcinoma and in normal gastric tissue. Cancer Res 1989, 49, 745-752.
66. 66. Takada A, Ohmori K, Takahashi N, et al. Adhesion of human cancer cells to vascular endothelium mediated by a carbohydrate antigen, sialyl Lewis A. Biochem Biophys Res Commun 1991, 179, 713-719.
67. x antigen correlates with poor survival in patients with colorectal carcinoma: clinicopathological and immunohistochemical study. Cancer Res 1993, 53, 3632-3637.
68. 68. Groves RW, Allen MH, Ross EL, Ahsan G, Barker JN, MacDonald DM. Expression of selectin ligands by cutaneous squamous cell carcinoma. Am J Pathol 1993, 143, 1220-1225.
69. 69. Albelda SM. Role of integrins and other cell adhesion molecules in tumor progression and metastasis. Lab Invest 1993, 68, 4-17.
70. 70. Hart I, Hogg N. Cell adhesion and cancer. Monograph. New York, Cold Spring Harbor Laboratory Press, 1995.
71. 71. Blasi F. Urokinase and Urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness. BioEssays 1993, 15, 105-111.
72. 72. Pollanen J, Hedman K, Nielsen LS, Dano K, Vaheri A. Ultrastructural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contacts. J Cell Biol 1988, 106, 87-95.
73. 73. Xue W, Mizukami I, Todd RF, Petty RH. Urokinase-type plasminogen activator associates with β1 and β3 integrins of fibrosarcoma cells: dependence on extracellular matrix components. Cancer Res 1997, 57, 1682-1689.
74. 74. Wei Y, Waltz DA, Roa N, Drummond RJ, Rosenberg S, Chapman HA. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 1994, 269, 32380-32388.
75. 75. Wei Y, Lukashev D, Simon DI, et al. Regulation of integrin function by the urokinase receptor. Science 1996, 273, 1551-1555.
76. 76. Pyke C, Kristensen P, Ralfkiaer E, et al. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 1991, 138, 1059-1067.
77. 77. Janicke F, Schmitt M, Hafter R, et al. Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 1990, 4, 69-78.
78. 78. Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N, Fennelly JJ, Andreasen P. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 1990, 50, 6827-6829.
79. 79. Duggan C, Maguire T, McDermott E, O'Higgins N, Fennelly JJ, Duffy MJ. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer. Int J Cancer 1995, 61, 597-600.
80. 80. Kim SJ, Shiba E, Taguchi, T, et al. Urokinase type plasminogen activator receptor is a novel prognostic factor in breast cancer. Anticancer Research 1997, 17, 1373-1378.
81. 81. Ganesh S, Sier CF, Griffioen G, et al. Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res 1994, 54, 4065-4071.
82. 82. Nekarda H, Schmitt M, Ulm K, et al. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res 1994, 54, 2900-2907.
83. 83. Xing RH, Rabbani SA. Overexpression of urokinase receptor in breast-cancer cells results in increased tumor invasion, growth and metastasis. Int J Cancer 1996, 67, 423-429.
84. 84. Achbarou A, Kaiser S, Tremblay G, et al. Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res 1994, 54, 2372-2377.
85. 85. Hearing VJ, Law LW, Corti A, Appella E, Blasi F. Modulation of metastatic potential by cell surface urokinase of murine melanoma cells. Cancer Res 1988, 48, 1270-1278.
86. 86. Mohanam S, Chintala SK, Go Y, et al. In vitro inhibition of human glioblastoma cell line invasiveness by antisense uPA receptor. Oncogene 1997, 14, 1351-1359.
87. 87. Kook YH, Adamski J, Zelent A, Ossowski L. The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. Embo J 1994, 13, 3983-3991.
88. 88. Stetler Stevenson WG. Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev 1990, 9, 289-303.
89. 89. Montgomery AM, Mueller BM, Reisfeld RA, Taylor SM, DeClerck YA. Effect of tissue inhibitor of the matrix metalloproteinases-2 expression on the growth and spontaneous metastasis of a human melanoma cell line. Cancer Res 1994, 54, 5467-5473.
90. 90. Poulsom R, Pignatelli M, Stetler Stevenson WG, et al. Stromal expression of 72kda type IV collagenase (MMPa-2) and TIMP-2 mRNAs in colorectal neoplasia. Am J Pathol 1992, 141, 389-396.
91. 91. Basset P, Bellocq JP, Wolf C, et al. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 1990, 348, 699-704.
92. 92. Muler D, Wolf C, Abecassis J, et al. Increased stromelysin 3 gene expression is associated with increased local invasiveness in head and neck squamous cell carcinomas. Cancer Res 1993, 53, 165-169.
93. 93. Newell KJ, Witty JP, Rodgers WH, Matrisian LM. Expression and localization of matrix-degrading metalloproteinases during colorectal tumorigenesis. Mol Carcinog 1994, 10, 199-206.
94. 94. Ahmad A, Marshall JF, Basset P, Anglard P, Hart IR. Modulation of human stromelysin three promoter and gene expression by human breast cancer. Int J Cancer 1997, 13(2), 290-296.
95. 95. Wang X, Fu X, Brown PD, Crimmin MJ, Hoffman RM. Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumour growth and spread in a patient-like orthotopic model in nude mice. Cancer Res 1994, 54, 4726-4728.
96. 96. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990, 82, 4-6.
97. 97. Liotta LA, Kleinerman J, Saidel GM. Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res 1974, 34, 997-1004.
98. 98. Craft PS, Harris AL. Clinical prognostic significance of tumour angiogenesis. Ann Oncol 1994, 5, 305-311.
99. 99. Risau W. What, if anything, is an angiogenic factor? Cancer Metastasis Rev 1996, 15, 149-151.
100. 100. Claffey KP, Robinson GS. Regulation of VEGF/VPF expression in tumor cells: consequences for tumor growth and metastasis. Cancer Metastasis Rev 1996, 15, 165-176.
101. 101. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993, 362, 841-844.
102. 102. Rastinejad F, Polverini PJ, Bouck NP. Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell 1989, 56, 345-355.
103. 103. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994, 265, 1582-1584.
104. 104. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma [see comments]. Cell 1994, 79, 315-328.
105. 105. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995, 1, 27-31.
106. 106. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88, 277-285.
107. 107. Teicher BA. A systems approach to cancer therapy. (Antioncogenics+standard cytotoxics → mechanism(s) of interaction). Cancer Metastasis Rev 1996, 15, 247-272.
108. 108. Ingber D, Fujita T, Kishimoto S, et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990, 348, 555-557.
109. 109. Maione TE, Gray GS, Petro J, et al. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 1990, 247, 77-79.
110. 110. Pasqualini R, Koivunen E, Rouslahti E. αv integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnology 1997, 15, 542-546.
111. 111. Brooks PB, Clark AF, Ceresh DA. Requirement of vascular integrin αvβ3 for angiogenesis. Science 1994, 264, 569-571.
112. 112. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarker FH, Cheresh D. Anti integrin αvβ3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995, 96, 1815-1822.
113. 113. Hammes HP, Brownlee M, Jonczyk A, Sutter A, Preissner KT. Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nat Med 1996, 2, 529-533.